AHA Statement Offers Guidance on Sleep-Disordered Breathing and Cardiac Arrhythmias in Adults
Cohort studies support strong associations between sleep-disordered breathing (SDB) and cardiac arrhythmia, but no high-level evidence from randomized trials yet supports a role for SDB intervention in rhythm control.
A new scientific statement from the American Heart Association (AHA) tackles an often undiagnosed but prevalent health problem — sleep-disordered breathing (SDB) — and underscores its connection with cardiac arrhythmogenesis.
“Strong evidence indicates that sleep-disordered breathing can lead to consequences such as autonomic nervous system fluctuations, recurrent hypoxia and alterations in carbon dioxide/acid-base status, which can directly affect cardiac function,” says Dr. Mehra, who is Director of Research in Cleveland Clinic’s Sleep Disorders Center and holds appointments in its Respiratory Institute and Heart, Vascular & Thoracic Institute. “Our panel’s data synthesis is designed to increase knowledge and awareness of the existing science in this area.”
“The association of sleep apnea and obesity with atrial fibrillation has made identification and treatment of sleep-disordered breathing and weight loss an important part of lifestyle and risk factor reduction in the treatment of atrial fibrillation,” adds Dr. Chung, a staff cardiologist in the Section of Cardiac Pacing and Electrophysiology. She also chaired the 2020 AHA scientific statement on lifestyle and risk factor modification for reduction of atrial fibrillation.
The SDB/arrhythmia connection
Nearly 1 billion individuals worldwide suffer from SDB, which is associated with excessive cardiopulmonary morbidity. Abundant evidence from mechanistic studies indicates that the physiological stress of SDB has sustained biological effects, which alter cardiovascular substrate and increase risk for cardiac arrhythmogenesis (Figure). In uncontrolled studies, treatment of SDB has been shown to reduce recurrence of arrhythmia after interventions such as catheter ablation and cardioversion for atrial fibrillation (AF).
AHA statement at a glance
The evidence for the scientific statement came from detailed literature searches in PubMed, Web of Science and Scopus conducted by the author panel. Selected publications consisted of English-language original articles, guideline statements and review articles.
The statement was peer reviewed by outside experts in epidemiology and clinical, translational and experimental research focused on SDB or cardiac arrhythmias. The panel’s findings are not formal clinical recommendations but rather considerations and suggestions for best clinical practice, based on at least 80% agreement among panel members.
The panel’s key conclusions include the following:
Day-night patterning and circadian biology of SDB-induced pathophysiological sequelae jointly influence the structural and electrophysiological cardiac substrate, creating an ideal milieu for arrhythmogenesis.
Cohort studies support strong associations between SDB and cardiac arrhythmia, providing evidence that discrete respiratory events trigger atrial and ventricular arrhythmic events.
Observational evidence suggests that treating SDB attenuates AF recurrence after rhythm control interventions, but there is currently no high-level evidence from randomized trials supporting a role for SDB intervention in rhythm control.
Opportunities exist to optimize SDB screening, characterize SDB predictive metrics and underlying pathophysiology, elucidate sex- and race/ethnicity-specific influences in SDB, assess the role of mobile health innovations, and prioritize conduct of rigorous and sufficiently powered clinical trials.
Additional observations of note
SDB subtypes relevant to the AHA document include obstructive sleep apnea (OSA), central sleep apnea (CSA), and CSA–Cheyne-Stokes breathing (CSB).
Regarding OSA, the panel notes that symptom-based screening questionnaires have limited predictive value in patients with AF because few of these individuals have daytime sleepiness. However, a validated OSA screening instrument in paroxysmal AF that combines neck circumference, age, body mass index and snoring holds promise. No reliable screening tools are available for CSA. The associations between cardiac dysfunction and CSA and CSB are likely to be bidirectional, the panel concludes.
Among existing guidelines underscored by the panel were recommendations from the European Society of Cardiology (ESC) for prudent treatment of SDB in patients with AF and for inclusion of the presence of OSA in risk stratification, as well as recommendations from the ESC and the AHA for SDB screening in patients with documented or suspected bradycardia or conduction disorder.
“We were very careful to state that identification of SDB and diagnostic testing and treatment should be confined to patients for whom there is a high index of suspicion for sleep apnea,” Dr. Mehra says. “SDB should be a consideration in those who are deemed at risk who have atrial fibrillation or other cardiac arrhythmias, but current evidence does not support universal screening.”
Next research priorities
While noting that many observational studies suggest that treatment of SDB improves AF outcomes, the panel identifies confirmation of this association in randomized controlled trials (RCTs) as a research priority. “Currently there are only small or limited randomized studies that have addressed SDB and AF, and they have shown conflicting results,” Dr. Chung says.
“We definitely need adequately powered, rigorously designed RCTs to ascertain whether intervening in patients with SDB actually improves arrhythmia outcomes,” Dr. Mehra adds. “The bulk of the data we have are for AF, and research is needed on other arrhythmias and on the impact of other factors, such as health disparities.”
Another panel priority is RCTs examining continuous positive airway pressure and newer therapies — such as neurostimulation, supplemental oxygen and medication — for treating SDB in people with arrhythmias, including ways to optimize treatment adherence.
“It appears that responses to different interventions vary among individuals,” Dr. Mehra observes. “Therefore, if diagnostic testing is consistent with OSA, a patient-provider discussion should then include an understanding of patient preferences. This includes exploring the range of therapeutic options available based on the severity and subtype of sleep-disordered breathing, such as lifestyle modification and interventions ranging from oral appliances to upper airway surgery or positive airway pressure.”
An additional perspective
“My hope is that this AHA statement will increase global awareness of the high prevalence of SDB among patients with cardiovascular disease in general and rhythm disorders in particular,” says Michael Faulx, MD, a Cleveland Clinic cardiologist with a special interest in the cardiovascular effects of sleep apnea. “The recommended routine screening will undoubtedly allow more symptomatic SDB patients to benefit from diagnosis and treatment. I also believe the AHA statement will foster a greater national interest in organizing well-designed mechanistic trials that explore the benefit of diagnosing and treating SDB with the goal of improving cardiovascular outcomes.”